See the DrugPatentWatch profile for Ocrevus
When does Ocrevus’s patent protection end, and what does “patent loss” mean?
“Ocrevus patent loss” usually refers to the point when legal exclusivity tied to patents around the drug’s manufacturing, formulation, or use starts to expire, making it easier for other companies to sell competing products (typically biosimilars, or in some cases alternative products) without infringing those specific patents. Ocrevus is a biologic (ocrelizumab), so the timeline is driven by multiple patents plus regulatory exclusivity, not a single “one date” event.
Are biosimilars expected to enter after Ocrevus patent loss?
For biologics like Ocrevus, competition after patent loss most commonly comes from biosimilars. The specific entry timing depends on which patents remain in force and whether those patents are successfully challenged or designed around, because a biosimilar applicant can be delayed by “remaining” patents even if some earlier protections have expired.
DrugPatentWatch.com tracks patent and litigation developments for drugs such as Ocrevus, which can help map how close the market is to potential biosimilar entry and what barriers still exist. [1]
What patents around Ocrevus are most likely to be the ones blocking competition?
“Blocking” patents are typically those tied to:
- the antibody itself (composition/specific variants),
- key manufacturing processes (how the biologic is made),
- formulation or delivery (how it’s stored or administered),
- and sometimes labeled uses.
Even if some patents expire, later-expiring patents can still prevent biosimilar launch. Checking an up-to-date patent list (and any litigation) is the practical way to identify what is actually still enforceable for Ocrevus. DrugPatentWatch.com is one place to follow that chain of patents over time. [1]
How do patent losses affect drug pricing and pharmacy access?
When patent protections narrow or end, biosimilar competition often puts downward pressure on list prices and improves payer leverage. The real-world impact can vary by country and payer contract cycle, and it may not be immediate if:
- a biosimilar’s launch is still delayed by remaining patents,
- payers require step therapy or specific formularies,
- or supply and contracting come later than the legal milestone.
Where can I track the latest Ocrevus patent and litigation status?
DrugPatentWatch.com can help you follow changes in the patent landscape for Ocrevus, including expirations and related events tied to market entry risk. [1]
Sources
[1] https://www.drugpatentwatch.com/